Finance
Results: 18745-18756 of 40800

Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma

Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program








